The Lynx Group
Cholangiocarcinoma News

Periadjuvant Approaches to Biliary Tract Cancers Offer Hope for Improved Outcomes

March 2021, Vol 2, No 1

A periadjuvant, or perioperative, approach to the treatment of biliary tract cancers, including cholangiocarcinoma (CCA), has several potential advantages that may offer an opportunity to improve outcomes in these diseases, said James Harding, MD, Regional Director, Early Drug Development, Memorial Sloan Kettering Cancer Center, New York, NY, at the 2020 Annual Cholangiocarcinoma Summit.

Periadjuvant Treatment

Periadjuvant treatment is “elevating the idea of systemic therapy in the treatment of patients with biliary tract cancers,” said Dr Harding. “Surgery is the curative modality here. However, we often see a metastatic failure, and thus the application of systemic therapies at earlier times in the disease and around surgery may become critically important.”

With standard approaches, including adjuvant treatment after tumor resection, disease recurrence and death from cancer still remains high at 5 years.

“The idea of a perioperative approach is to treat patients earlier,” Dr Harding said. “There are several pros to this. First, we may be able to apply a systemic therapy to downstage the disease, which would hopefully improve outcome. We could more rapidly treat micrometastatic disease, which we know is critical in failure for many of these patients, particularly with intrahepatic cholangiocarcinoma.”

“You also have patients who have a better performance status presurgically, and they may be able to tolerate more aggressive therapy. It’s also possible that would prevent surgeries in those with poor biologies,” Dr Harding suggested.

The drawbacks to a periadjuvant approach to therapy are that the window of opportunity for surgery may close while systemic therapy is being administered, because patients may have disease refractory to the proposed systemic therapy, and overtreatment is a possibility.

Hypothesis-generating data suggest that administering treatment upfront may improve outcomes, according to Dr Harding.

A propensity score matched analysis by Yadav and colleagues indicated that neoadjuvant chemotherapy led to a higher probability of survival compared with adjuvant chemotherapy in patients with stage I, stage II, or stage III biliary tract cancers.1 Possible selection bias would necessitate prospective evaluation of the periadjuvant approach.

The application of perioperative chemotherapy versus adjuvant therapy in patients with resectable intrahepatic CCAs is being assessed in a randomized phase 2 clinical trial. The primary outcome is event-free survival at 24 months, Dr Harding said. The study objective is to determine the intrahepatic CCA genotype, using next-generation sequencing in tumor specimens and in tumor-derived cell-free DNA; the study will also define the concordance between tumor and cell-free DNA genotype. In addition, cell-free DNA as a potential marker of minimal residual disease is also being assessed.2

Investigational periadjuvant approaches to CCA include combination chemotherapies and locoregional therapy, precision medicine, and immunotherapeutics. A recent study showed that combination cytotoxic therapies induced an overall response rate of 60%, a median progression-free survival of 11.8 months, and median overall survival of 19.2 months in the locally advanced or metastatic setting.3

The feasibility of the combination of gemcitabine, cisplatin, and nab-paclitaxel is also being explored as neoadjuvant therapy for patients with locally advanced intrahepatic CCA.

Another potential approach is hepatic arterial infusion pump therapy. A small, 2-center, phase 2 clinical trial demonstrated “excellent disease control” with this approach,4 said Dr Harding.

Regional therapies under investigation in patients with locally advanced intrahepatic CCA include the combination of chemotherapy with Y-90, which demonstrated an objective response rate of 41% along with median overall survival of 22 months, in a recent phase 2 clinical trial by Edeline and colleagues.5

“When we think about the regional therapeutics in an operative candidate, one question that comes up is the potential for toxicities and potential delay in operation,” he said.

Damage to the biliary tree is possible with hepatic arterial infusion pump therapy, and abnormalities in liver function tests have been reported with Y-90.

Role of Precision Medicine

Biliary tract cancers have several potentially actionable gene targets, suggesting a role for precision medicine, Dr Harding said. This suggests a “potential way to specifically link patients in a perioperative or periadjuvant approach to potentially enhance response and decrease the risk of recurrence,” he noted. Pemigatinib (Pemazyre) received FDA approval for the treatment of patients with unresectable CCA and FGFR2 rearrangement or fusion based on phase 2 clinical trial data.

Considerations for precision medicine include the difficulty in identifying low-frequency mutations in a rare disease, because 1 in 4 patients do not have enough tissue on a fine-needle aspiration or core biopsy to identify adequately a genomic mutation, and genomic alterations are present in only approximately 40% of patients with biliary tract cancers. In addition, polyclonal resistance often occurs, complicating patient selection for precision medicine.

Immunotherapy, Chemotherapy

According to Dr Harding, thus far, immunotherapy has disappointed in the setting of biliary tract cancers. “We clearly see that single-agent anti–PD-1 therapy in a nonselected patient population appears to have limited activity,” Dr Harding said.

“Perhaps by looking at PD-1 or PD-L1 expression in the tumor, we can slightly enrich antitumor activity, and certainly, we see it in the microsatellite instability-high subset. For the majority of patients, we need to have more. The majority of patients on genotyping seem to have cold tumors. Thus, novel combinations are going to need to be explored,” Dr Harding added.

The combination of chemotherapy and immunotherapy is an intriguing possibility.

References

  1. Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019;45:1432-1438.
  2. Abou-Alfa GK, Andersen JB, Chapman W, et al. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016;7:819-827.
  3. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824-830.
  4. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:60-67.
  5. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51-59.

Related Items

What’s Next in Immunotherapy in Biliary Tract Cancers?
March 2021, Vol 2, No 1
The rationale for immunotherapy in biliary tract cancers is strong, because these cancers are inflammatory in nature, according to Abby Siegel, MD, MS, Executive Director and PDT Lead, Hepatobiliary Oncology, Global Clinical Development at Merck. Inroads are being made into biomarkers predictive of response to immunotherapy in biliary cancers, Dr Siegel said at the 2020 Annual Cholangiocarcinoma Summit.
The Updated Staging System for Cholangiocarcinoma: Implications for Hilar and Intrahepatic Disease
March 2021, Vol 2, No 1
Flavio Rocha, MD, Hepatopancreatobiliary Surgeon, Virginia Mason Medical Center, Director of Research, Digestive Disease Institute, and Associate Medical Director of the Floyd and Delores Jones Cancer Institute, Seattle, WA, provided an overview of the changes made in the 8th edition of the AJCC’s tumor, node, metastasis (TNM) staging system at the 2020 Annual Cholangiocarcinoma Summit. These changes have direct implications for the management of patients with hilar or intrahepatic CCA.
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Gallbladder Cancer: Novel Approaches to Therapy Are Needed
December 2020, Vol 1, No 3
The current standard of care for the systemic treatment of patients with advanced gallbladder cancer is the chemotherapy combination of gemcitabine and cisplatin, which is suboptimal, yielding only modest benefit, said Richard Kim, MD, Section Chief, Gastrointestinal Medical Oncology, Moffitt Cancer Center, Tampa, FL, at the 2020 Cholangiocarcinoma Summit.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.
Role of Liver Transplant in Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Liver transplant is emerging as a treatment option in patients with unresectable hilar or intrahepatic cholangiocarcinoma (CCA), with accumulating data supporting transplant protocols in patients with early-stage CCA.
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: